GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE

Similar documents
Detection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection

Kalliopi Azariadi, Pinelopi Arvaniti, Nikolaos Gatselis, George N. Dalekos, Kalliopi Zachou

Background. ΝΑ therapy in CHBe- until HBsAg clearance. (EASL guidelines 2012)

Risk stratification in PBC

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

Primary Biliary Cholangitis

Presentation and mortality of primary biliary cirrhosis in older patients

Discontinuation of Nucleotide or Nucleoside Analogue therapy for Chronic Hepatitis B infection

New insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine

Diagnosis and Management of PBC

TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)

Primary Biliary Cholangitis

P rimary biliary cirrhosis (PBC) is an immune mediated

PBC features and management in the era of UDCA and Budesonide

Pediatric PSC A children s tale

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam

Ka-Shing Cheung, MBBS, MPH 1, Wai-Kay Seto, MD 1,2, James Fung, MD 1,2, Ching-Lung Lai, MD 1,2 and Man-Fung Yuen, MD, PhD 1,2

Primary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

MY DISCUSSION GUIDE. Personalize your treatment plan for primary biliary cholangitis (PBC).

WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.

Primary biliary cirrhosis (PBC) is an autoimmune

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Primary Biliary Cirrhosis

Ocaliva (obeticholic acid tablets)

Current Concepts in the Management and Treatment of PBC & PSC

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Patterns of abnormal LFTs and their differential diagnosis

LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

Towards Precision Medicine in Primary Biliary Cholangitis

Patterns of abnormal LFTs and their differential diagnosis

CrackCast Episode 28 Jaundice

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score

MY DISCUSSION GUIDE. Get the most out of your OCALIVA treatment.

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto

Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks

Morning Report Presentation. Sarah Hughes, MD January 11, 2005

R ecent estimates suggest that there are

Alcoholism and Alcohol Liver Disease from a Transplant Hepatology Perspective

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

Current concepts in hepatitis E. Does it exist in Greece?

Approach to Abnormal Liver Tests

PBC treatment: the present and future. Maggie Bassendine Professor of Hepatology

Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785

Investigations before OLT, Immunosuppression and rejection, Follow up after OLT.

Program Disclosure. This activity is supported by an educational grant from Intercept Pharmaceuticals.

Chronic Cholestatic Liver Diseases

Pretreatment Evaluation

Overview of PSC Making the Diagnosis

Autoimmune Hepatitis: Defining the need for Liver Transplantation

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Module 1 Introduction of hepatitis

Forward-looking Statements

Intron A Hepatitis C. Intron A (interferon alfa-2b) Description

Hepatology for the Nonhepatologist

Hépatopathies auto-immunes

Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015

During the course of the 12 month fellowship, candidates will attend at least one international liver meeting (generally AASLD).

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

The informed patient. Primary biliary cirrhosis (PBC) Primary sclerosing cholangitis (PSC)

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT

Treatment of chronic hepatitis delta Case report

WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT

Autoimmune hepatitis

Clinical Significance of Serum Bilirubin Levels Under Ursodeoxycholic Acid Therapy in Patients With Primary Biliary Cirrhosis

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Hepatocellular Carcinoma: Diagnosis and Management

World Health Organization. Western Pacific Region

Chronic Hepatitis C. Risk Factors

Hepatitis C Update on New Treatments

Pretreatment Evaluation

Approach to the Patient with Liver Disease

Hepatology For The Nonhepatologist

Liver cirrhosis There s more of it out there than you think!

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Jaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

SOMEONE YOU CARE ABOUT HAS PBC Learn about primary biliary cholangitis (PBC), the treatment, and ways you can help

Primary biliary cholangitis

Title: Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA

OCALIVA (obeticholic acid) oral tablet

Primary Sclerosing Cholangitis Medical Management

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Albumin-to-bilirubin score for assessing the in-hospital death in cirrhosis

Patient Information Leaflet Liver Transplantation Assessment

Healthy Liver Cirrhosis

Physical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:

Transcription:

GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE Kalliopi Azariadis 1, Nikolaos K. Gatselis 1, Kalliopi Zachou 1, Vasiliki Lygoura 1, Pinelopi Arvaniti 1, Eirini I. Rigopoulou 1, Georgia Papadamou 1, George K. Koukoulis 2, George N. Dalekos 1 1 Department of Medicine and Research Laboratory of Internal Medicine, Medical School, University of Thessaly, Larissa, Greece. 2 Department of Pathology, Medical School, University of Thessaly, Larissa, Greece.

Introduction Primary biliary cholangitis is an autoimmune hepatic disease arising from an interplay between genetic and environmental factors Prevalence is characterized by important geographical differences possibly attributed to the influence of infectious factors (viruses, bacteria) and xenobiotics Van de Water J. Hepatology 2001 Long SA, Autoimmun Rev 2002

Aim Our aim was to describe The geographical and seasonal distribution of PBC in central Greece The basic characteristics of our patients at presentation Response to treatment Prognosis

Patients and Methods 482 PBC patients followed at Department of Medicine and Research Laboratory of Internal Medicine, University of Thessaly during a sixteen year time period 2000-2015

number of patients Results I 150 100 total group males females Age distribution / : 6.4/1 Same age distribution (56.3±13.7 years) 50 0 10 20 30 40 50 60 70 80 90 age

Results II Mean yearly prevalence 32 patients/year Seasonal preference during spring

Results III Hashimoto thyroiditis 12.9% Breast cancer 3.5%

Results IV Symptoms at presentation Pruritus 25.9% Xerostomia / dry eyes 14.9% Fatigue 11.8% Arthralgia / Myalgia 11.2% Abdominal Pain 8.7% Rash 1.5% End stage liver disease symptoms : Ascites Variceal bleeding Hepatic encephalopathy Jaundice 2.5%

Results V Symptoms at presentation p=0.014 p=0.06

Results VI Presence of cirrhosis at presentation cirrhotic Factors associated with the presence of cirrhosis at baseline (multivariate analysis) no-cirrhotic 232/281 (82.6%) patients Stage 0-I-II 49/281 (17.4%) patients Stage III-IV

Results VII positive association with AST, ALT, ALP, γgt, IgM, Mayo Risk Score positive association with AST, γgt, IgM

Results VIII GLOBE SCORE Responders ( 0.30) Non Responders (>0.30) Parameters Age at UDCA treatment initiation 1 st year UCDA treatment (bilirubin, ALP, Αlbumin, Platelets) Lammers, Gastroenterology 2015

Results IX GLOBE SCORE in a Greek Population (n=271) Negative predictive factors for response to treatment: Cirrhosis (OR=22.312, 95% CI: 5.988-83.137, P<0.001) Lower educational level (OR=2.993, 95% CI: 1.441-6.217, P<0.01) The 5-, 10-, and 15-year survival or transplant-free rates for nonresponders were 84%, 50%, and 42%, respectively.

Results X Patient Outcome (mean follow up 5.1 years - 15.7 years range) Negative prognostic factors for liver related events

Results XI PBC prevalence in Thessaly 582 patients/ 1 million residents 19 regions with a prevalence >800 patients/ million residents *439/482 (91%) patients were residents in Thessaly at the time of presentation

Conclusions PBC has a high prevalence in Thessaly Geographical and seasonal distribution implies relation with environmental factors (atmosphere pollution, water pollution with toxic waste, lignite rich soil etc.)

Conclusions A large portion of patients is asymptomatic, with an early histological stage at the time of diagnosis Male patients are more likely to be cirrhotic at presentation Poor prognosis is related to the presence of cirrhosis, older age, increased bilirubin and alcohol consumption

Conclusions The GLOBE SCORE has an optimal application to the Greek population and it must be used to stratify patients with a worse chance of responding to UDCA treatment

Thank you for your attention!